Clinical Trial Update: A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of Levodopa-carbidopa intestinal gel (LCIG) for non-motor symptoms in advanced Parkinson's disease has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Levodopa-carbidopa intestinal gel (levodopa-carbidopa intestinal gel)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-02-08